Revista Espanola De Medicina Nuclear E Imagen Molecular最新文献

英文中文

Un caso raro de adenocarcinoma bilateral sincrónico del cuerpo ciliar en [18F]FDG PET/TC y [68Ga]Ga-PSMA PET/TC [18F]FDG PET/TC和[68Ga]Ga-PSMA PET/TC的纤毛体双侧同步腺癌罕见病例

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2026-01-01 DOI: 10.1016/j.remn.2025.500181

N. Aydinbelge Dizdar , E. Tatci , O. Ozmen

引用次数: 0

Imágenes de enfisema subcutáneo masivo y resorción completa detectadas en [18F]FDG PET/TC [18F]FDG PET/TC检测到大量皮下肺气肿和完全吸收的图像

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2026-01-01 DOI: 10.1016/j.remn.2025.500180

M.T. Tatoğlu , H. Uslu

引用次数: 0

Pretratamiento 18F-FDG PET/TC para predecir la supervivencia de los pacientes con tumores neuroendocrinos hepáticos 预处理18F-FDG PET/TC以预测肝神经内分泌肿瘤患者的生存

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2026-01-01 DOI: 10.1016/j.remn.2025.500198

Y. Zhang , G. Liu , L. Zhong , B. Li , Y. Zhang

Objective

To investigate the prognostic value of pretreatment 2-[¹⁸F]-fluoro-2-deoxy-d-glucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) in patients with hepatic neuroendocrine tumors (HNET).

Methods

In total, 41 patients were included in this study. PET-derived metabolic parameters, including maximum and mean standardized uptake values (SUV_max and SUV_mean, respectively), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), of the tumors were measured. Meanwhile, clinical data, including tumor pathological findings such as the Ki-67 index were also assessed. Progression-free survival (PFS) and overall survival (OS) were evaluated. Univariate and multivariate analyses were performed to predict the prognostic value of clinical variables and PET-derived metabolic parameters in HNET patients. Correlation between PET-derived metabolic parameters and Ki-67 was estimated.

Results

Univariate analyses revealed that among PET-derived metabolic parameters, SUV_max, SUV_mean, and TLG were significant prognostic factors for OS (P<.05). Among clinical variables, the Ki-67 index and radical surgical resection were significant factors for both PFS and OS (P<.05). In multivariate analyses, only Ki-67 index was an independent prognostic factor for both PFS and OS (P<.05). Ki-67 index presented correlates with SUV_max and SUV_mean (R=.566, P<.001; R=.493, P=.001, respectively).

Conclusions

In patients with HNET, the Ki-67 index was an independent prognostic factor for both PFS and OS, while SUV_max, SUV_mean, and TLG measured on pretreatment ¹⁸F-FDG PET/CT scans were prognostic factors for predicting OS. Ki-67 index also presented correlates with SUV_max and SUV_mean. ¹⁸F-FDG-PET may be useful as quantitative predicting prognostic imaging biomarkers, especially in poorly differentiated HNET.

目的探讨预处理2-[18F]-氟-2-脱氧-d-葡萄糖（18F- fdg）正电子发射断层扫描/计算机断层扫描（PET/CT）对肝神经内分泌肿瘤（HNET）患者的预后价值。方法本研究共纳入41例患者。测量pet衍生的代谢参数，包括肿瘤的最大和平均标准化摄取值（分别为SUVmax和SUVmean）、代谢肿瘤体积（MTV）和病变总糖酵解（TLG）。同时对肿瘤病理表现Ki-67指数等临床资料进行评估。评估无进展生存期(PFS)和总生存期(OS)。通过单因素和多因素分析来预测临床变量和pet衍生代谢参数在HNET患者中的预后价值。估计pet衍生代谢参数与Ki-67之间的相关性。结果单因素分析显示，在pet衍生的代谢参数中，SUVmax、SUVmean和TLG是OS的重要预后因素（P< 0.05）。在临床变量中，Ki-67指数和根治性手术切除是影响PFS和OS的重要因素（P< 0.05）。在多变量分析中，Ki-67指数是PFS和OS的独立预后因素（P< 0.05）。Ki-67指数与SUVmax和SUVmean存在相关性（R= 0.566， P= 0.001； R= 0.493， P= 0.001）。结论在HNET患者中，Ki-67指数是PFS和OS的独立预后因素，而预处理18F-FDG PET/CT扫描测量的SUVmax、SUVmean和TLG是预测OS的预后因素。Ki-67指数与SUVmax和SUVmean也存在相关性。18F-FDG-PET可作为定量预测预后的影像学生物标志物，特别是在低分化的HNET中。

{"title":"Pretratamiento 18F-FDG PET/TC para predecir la supervivencia de los pacientes con tumores neuroendocrinos hepáticos","authors":"Y. Zhang , G. Liu , L. Zhong , B. Li , Y. Zhang","doi":"10.1016/j.remn.2025.500198","DOIUrl":"10.1016/j.remn.2025.500198","url":null,"abstract":"<div><h3>Objective</h3><div>To investigate the prognostic value of pretreatment 2-[<sup>18</sup>F]-fluoro-2-deoxy-<span>d</span>-glucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) in patients with hepatic neuroendocrine tumors (HNET).</div></div><div><h3>Methods</h3><div>In total, 41 patients were included in this study. PET-derived metabolic parameters, including maximum and mean standardized uptake values (SUV<sub>max</sub> and SUV<sub>mean</sub>, respectively), metabolic tumor volume (MTV), and total lesion glycolysis (TLG), of the tumors were measured. Meanwhile, clinical data, including tumor pathological findings such as the Ki-67 index were also assessed. Progression-free survival (PFS) and overall survival (OS) were evaluated. Univariate and multivariate analyses were performed to predict the prognostic value of clinical variables and PET-derived metabolic parameters in HNET patients. Correlation between PET-derived metabolic parameters and Ki-67 was estimated.</div></div><div><h3>Results</h3><div>Univariate analyses revealed that among PET-derived metabolic parameters, SUV<sub>max</sub>, SUV<sub>mean</sub>, and TLG were significant prognostic factors for OS (<em>P</em><.05). Among clinical variables, the Ki-67 index and radical surgical resection were significant factors for both PFS and OS (<em>P</em><.05). In multivariate analyses, only Ki-67 index was an independent prognostic factor for both PFS and OS (<em>P</em><.05). Ki-67 index presented correlates with SUV<sub>max</sub> and SUV<sub>mean</sub> (R=.566, <em>P</em><.001; R=.493, <em>P</em>=.001, respectively).</div></div><div><h3>Conclusions</h3><div>In patients with HNET, the Ki-67 index was an independent prognostic factor for both PFS and OS, while SUV<sub>max</sub>, SUV<sub>mean</sub>, and TLG measured on pretreatment <sup>18</sup>F-FDG PET/CT scans were prognostic factors for predicting OS. Ki-67 index also presented correlates with SUV<sub>max</sub> and SUV<sub>mean</sub>. <sup>18</sup>F-FDG-PET may be useful as quantitative predicting prognostic imaging biomarkers, especially in poorly differentiated HNET.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"45 1","pages":"Article 500198"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146006832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Más allá del estándar: Mejora en la detección del lecho prostático y los ganglios linfáticos regionales en los pacientes con cáncer de próstata mediante imágenes precoces y tardías de la PET/TC con [68Ga]Ga-PSMA-11 超越标准：使用[68Ga]Ga-PSMA-11的早期和晚期PET/ CT成像，改善前列腺癌患者的前列腺床和区域淋巴结的检测

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2026-01-01 DOI: 10.1016/j.remn.2025.500184

A. Aghaee , Z. Bakhshi , V. Roshanravan , N. Norouzbeigi , H. Dadgar , E. Askari , K. Aryana , S. Shafiei , S. Soltani , S. Sadeghpour

Objectives

This study aims to evaluate the diagnostic value of early static and delayed imaging in conjunction with standard ⁶⁸Ga-PSMA-11 PET/CT scans to detect prostate malignant lesions in prostate cancer patients.

Methods

138 prostate cancer patients underwent routine [⁶⁸Ga]Ga-PSMA-11 PET/CT imaging, 4-minute static acquisition post-injection, and delayed imaging 3 hours post-injection. The imaging results were analysed for lesion count, type, localisation, and maximum standardised uptake values.

Results

57.97% exhibited positive findings for pathologic prostatic lesions in the standard PET scans (SUVmax: 10.24). In contrast, early PET imaging detected lesions in 58.01% of patients (SUVmax of 5.86), while delayed scans revealed lesions suggestive of malignancy in 55.45% of patients (SUVmax of 12.79). The analysis demonstrated a statistically significant difference in SUVmax values across the time points (P<.001). Pathologic lymph nodes on Images 60 min p.i. were revealed by an SUV max 60 min p.i.: 15.78; this number for the first 4 min and after 3 hours were 7.36, 19.19, respectively. Metastatic bone lesions on WB were found in 38 patients, more than the ESI (n = 37) and DI (n = 24). In comparison, urinary bladder activity assessment was detectable with the WB imaging SUVmax 60 min 11.07. Even though the SUV max for ESI and DI were 6.95 and 31.97, respectively. In the statistical analysis, pathologic radiotracer uptake in tumour lesions was statistically higher in ESI and WB than in urinary bladder activity.

Conclusions

The findings indicate that neither early [⁶⁸Ga]Ga-PSMA-11 PET/CT nor delayed imaging significantly enhanced the overall detection rate of malignant lesions in prostate cancer patients. However, the early 4-minute post-injection acquisition of PET images proved beneficial for distinguishing local bladder invasion more effectively.

目的探讨早期静态和延迟成像结合68Ga-PSMA-11标准PET/CT扫描对前列腺癌患者前列腺恶性病变的诊断价值。方法138例前列腺癌患者行常规[68Ga]Ga-PSMA-11 PET/CT成像，注射后4分钟静态采集，注射后3小时延迟成像。结果57.97%的患者在标准PET扫描中表现为病理前列腺病变阳性（SUVmax: 10.24）。相比之下，58.01%的患者（SUVmax为5.86）在早期PET成像中发现病变，而55.45%的患者（SUVmax为12.79）在延迟扫描中发现提示恶性病变。分析表明，不同时间点的SUVmax值有统计学上的显著差异（P<.001）。病理淋巴结在60 min pi的图像上显示SUV最大60 min pi: 15.78；这一数字在前4分钟和后3小时分别为7.36和19.19。WB上发现转移性骨病变38例，高于ESI（37例）和DI（24例）。相比之下，膀胱活动评估可通过WB成像SUVmax 60 min 11.07检测到。尽管ESI和DI的SUV max分别为6.95和31.97。在统计分析中，病理放射性示踪剂在肿瘤病变中的摄取在ESI和WB中高于膀胱活动。结论早期[68Ga]Ga-PSMA-11 PET/CT及延迟显像均未显著提高前列腺癌患者恶性病变的整体检出率。然而，注射后早期4分钟的PET图像采集有助于更有效地识别局部膀胱侵犯。

{"title":"Más allá del estándar: Mejora en la detección del lecho prostático y los ganglios linfáticos regionales en los pacientes con cáncer de próstata mediante imágenes precoces y tardías de la PET/TC con [68Ga]Ga-PSMA-11","authors":"A. Aghaee , Z. Bakhshi , V. Roshanravan , N. Norouzbeigi , H. Dadgar , E. Askari , K. Aryana , S. Shafiei , S. Soltani , S. Sadeghpour","doi":"10.1016/j.remn.2025.500184","DOIUrl":"10.1016/j.remn.2025.500184","url":null,"abstract":"<div><h3>Objectives</h3><div>This study aims to evaluate the diagnostic value of early static and delayed imaging in conjunction with standard <sup>68</sup>Ga-PSMA-11 PET/CT scans to detect prostate malignant lesions in prostate cancer patients.</div></div><div><h3>Methods</h3><div>138 prostate cancer patients underwent routine [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT imaging, 4-minute static acquisition post-injection, and delayed imaging 3hours post-injection. The imaging results were analysed for lesion count, type, localisation, and maximum standardised uptake values.</div></div><div><h3>Results</h3><div>57.97% exhibited positive findings for pathologic prostatic lesions in the standard PET scans (SUVmax: 10.24). In contrast, early PET imaging detected lesions in 58.01% of patients (SUVmax of 5.86), while delayed scans revealed lesions suggestive of malignancy in 55.45% of patients (SUVmax of 12.79). The analysis demonstrated a statistically significant difference in SUVmax values across the time points (<em>P</em><.001). Pathologic lymph nodes on Images 60 min p.i. were revealed by an SUV max 60 min p.i.: 15.78; this number for the first 4 min and after 3hours were 7.36, 19.19, respectively. Metastatic bone lesions on WB were found in 38 patients, more than the ESI (n = 37) and DI (n = 24). In comparison, urinary bladder activity assessment was detectable with the WB imaging SUVmax 60 min 11.07. Even though the SUV max for ESI and DI were 6.95 and 31.97, respectively. In the statistical analysis, pathologic radiotracer uptake in tumour lesions was statistically higher in ESI and WB than in urinary bladder activity.</div></div><div><h3>Conclusions</h3><div>The findings indicate that neither early [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT nor delayed imaging significantly enhanced the overall detection rate of malignant lesions in prostate cancer patients. However, the early 4-minute post-injection acquisition of PET images proved beneficial for distinguishing local bladder invasion more effectively.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"45 1","pages":"Article 500184"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146006831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gammagrafía de tránsito gastrointestinal en la valoración del rectocele 直肠评价中的胃肠道转运性放射学e

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2026-01-01 DOI: 10.1016/j.remn.2025.500142

J.R. Infante , A. Utrera , R. Barco , M. Carmona , I. Gallarín , A. Baena , A. Martínez , C. Durán , N. Sicilia , J. Serrano

Aim

Rectocele can cause chronic constipation and altered quality of life. In the presence of severe symptomatology and lack of response to conservative treatment, gastrointestinal motor function should be assessed. The aim of this study was to assess the utility of gastrointestinal transit scintigraphy in this pathology, analyzing its position in international guidelines.

Material and methods

We retrospectively evaluated twelve women with rectocele and chronic constipation, range of 31-74 years, referred for scintigraphic study as an assessment prior to prolapse treatment. Defecography was altered in 12 and anorectal manometry in 8. Following international guidelines, a dose of [¹¹¹In]In-DTPA (37 mBq) was administered together with standardized food to assess liquid gastric emptying and small-bowel and colonic transit. Areas of interest were defined in these locations to calculate the geometric center.

Results

In 3 patients the radioisotopic study was normal, 3 showed a pattern of outlet obstruction, 3 colonic inertia, 2 slow small-bowel transit and 1 slow generalized transit. Thus, 50% of patients presented transit alterations not located in the rectosigmoid area.

Conclusion

Scintigraphy study provided useful information for the evaluation of patients with rectocele and constipation, influencing the diagnosis and therapeutic management. It proved to be a physiological method, providing both global and regional quantitative information. Like other authors, it is considered appropriate to use the study at the same level as the tests for the assessment of defecatory dynamics.

直肠膨出可引起慢性便秘和生活质量的改变。在存在严重症状且对保守治疗缺乏反应的情况下，应评估胃肠运动功能。本研究的目的是评估胃肠道转运显像在这种病理中的应用，分析其在国际指南中的地位。材料和方法我们回顾性评估了12名患有直肠前突和慢性便秘的妇女，年龄31-74岁，作为脱垂治疗前的评估。12例大便造影改变，8例肛肠测压改变。根据国际指南，将[111In]In-DTPA剂量（37 mBq）与标准化食物一起使用，以评估胃液排空和小肠和结肠运输。在这些位置定义感兴趣的区域以计算几何中心。结果放射性同位素检查正常3例，出口梗阻3例，结肠惯性3例，小肠慢运2例，全身慢运1例。因此，50%的患者表现出不位于直肠乙状结肠区域的中转性改变。结论显像研究为直肠前突伴便秘患者的诊断和治疗提供了有用的信息。它被证明是一种生理学方法，提供了全球和区域的定量信息。与其他作者一样，在评估排便动力学的测试水平上使用该研究被认为是适当的。

{"title":"Gammagrafía de tránsito gastrointestinal en la valoración del rectocele","authors":"J.R. Infante , A. Utrera , R. Barco , M. Carmona , I. Gallarín , A. Baena , A. Martínez , C. Durán , N. Sicilia , J. Serrano","doi":"10.1016/j.remn.2025.500142","DOIUrl":"10.1016/j.remn.2025.500142","url":null,"abstract":"<div><h3>Aim</h3><div>Rectocele can cause chronic constipation and altered quality of life. In the presence of severe symptomatology and lack of response to conservative treatment, gastrointestinal motor function should be assessed. The aim of this study was to assess the utility of gastrointestinal transit scintigraphy in this pathology, analyzing its position in international guidelines.</div></div><div><h3>Material and methods</h3><div>We retrospectively evaluated twelve women with rectocele and chronic constipation, range of 31-74years, referred for scintigraphic study as an assessment prior to prolapse treatment. Defecography was altered in 12 and anorectal manometry in 8. Following international guidelines, a dose of [<sup>111</sup>In]In-DTPA (37mBq) was administered together with standardized food to assess liquid gastric emptying and small-bowel and colonic transit. Areas of interest were defined in these locations to calculate the geometric center.</div></div><div><h3>Results</h3><div>In 3 patients the radioisotopic study was normal, 3 showed a pattern of outlet obstruction, 3 colonic inertia, 2 slow small-bowel transit and 1 slow generalized transit. Thus, 50% of patients presented transit alterations not located in the rectosigmoid area.</div></div><div><h3>Conclusion</h3><div>Scintigraphy study provided useful information for the evaluation of patients with rectocele and constipation, influencing the diagnosis and therapeutic management. It proved to be a physiological method, providing both global and regional quantitative information. Like other authors, it is considered appropriate to use the study at the same level as the tests for the assessment of defecatory dynamics.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"45 1","pages":"Article 500142"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146006827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tratamiento con microesferas de ácido poliláctico marcadas con [166Ho]Ho en paciente con hiperplasia nodular focal gigante 用[166Ho]Ho标记的聚乳酸微球治疗巨大局灶性结节增生患者

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2026-01-01 DOI: 10.1016/j.remn.2025.500204

J.J. Martin-Marcuartu , J.L. Vercher-Conejero , B. Hervás-Sanz , J. Valcarcel José , L. Llado Garriga , M. Cortes-Romera

引用次数: 0

Tratamiento con péptidos marcados con radionúclidos en los meningiomas refractarios: revisión actualizada y perspectivas clínicas 用放射性核素标记多肽治疗顽固性脑膜炎：最新综述和临床前景

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2026-01-01 DOI: 10.1016/j.remn.2025.500218

E. Abou. Jokh Casas , J.L. Vercher Conejero , A. Repetto , P. Bello Arques , T. Cambil Molina , A. Rodriguez Gasén , J.A. Vallejo Casas

The use of theragnostics in nuclear medicine has significantly advanced, particularly peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Meningiomas often overexpress somatostatin receptors (SSTR), making them potential candidates for PRRT. However, the lack of large-scale standardized trials limits its clinical application.

Meningiomas are the most common primary intracranial tumors; the treatment of choice for which is surgical resection or, if that's not possible, radiotherapy. However, some cases are refractory to standard treatments, leading to the exploration of other therapeutic options, such as targeted therapy with radioligands. Studies have demonstrated promising results with [¹⁷⁷Lu]Lu-DOTATATE in meningiomas expressing SSTR2, improving progression-free survival (PFS) in refractory cases.

Current evidence suggests that PRRT is a viable option for refractory meningiomas with high SSTR expression. However, further clinical trials are needed to establish standardized protocols, optimize patient selection criteria, and explore combination therapy strategies to improve outcomes. This review highlights the mechanisms, clinical applications, and future perspectives of [¹⁷⁷Lu]Lu-DOTATATE in meningiomas, providing insights into its expanding role in this pathology.

核医学诊疗学的应用有了显著的进步，特别是在神经内分泌肿瘤中的肽受体放射性核素治疗（PRRT）。脑膜瘤通常过度表达生长抑素受体（SSTR），使其成为PRRT的潜在候选者。然而，缺乏大规模的标准化试验限制了其临床应用。脑膜瘤是最常见的原发性颅内肿瘤；治疗的选择是手术切除，如果不可能的话，放射治疗。然而，一些病例对标准治疗难以治愈，导致探索其他治疗选择，如放射配体靶向治疗。研究表明，[177Lu]Lu-DOTATATE在表达SSTR2的脑膜瘤中具有良好的效果，可改善难治性病例的无进展生存期（PFS）。目前的证据表明，PRRT是高SSTR表达的难治性脑膜瘤的可行选择。然而，需要进一步的临床试验来建立标准化的方案，优化患者选择标准，并探索联合治疗策略以改善结果。本文综述了[177Lu]Lu-DOTATATE在脑膜瘤中的作用机制、临床应用和未来前景，为其在脑膜瘤病理中的作用提供了新的见解。

{"title":"Tratamiento con péptidos marcados con radionúclidos en los meningiomas refractarios: revisión actualizada y perspectivas clínicas","authors":"E. Abou. Jokh Casas , J.L. Vercher Conejero , A. Repetto , P. Bello Arques , T. Cambil Molina , A. Rodriguez Gasén , J.A. Vallejo Casas","doi":"10.1016/j.remn.2025.500218","DOIUrl":"10.1016/j.remn.2025.500218","url":null,"abstract":"<div><div>The use of theragnostics in nuclear medicine has significantly advanced, particularly peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Meningiomas often overexpress somatostatin receptors (SSTR), making them potential candidates for PRRT. However, the lack of large-scale standardized trials limits its clinical application.</div><div>Meningiomas are the most common primary intracranial tumors; the treatment of choice for which is surgical resection or, if that's not possible, radiotherapy. However, some cases are refractory to standard treatments, leading to the exploration of other therapeutic options, such as targeted therapy with radioligands. Studies have demonstrated promising results with [<sup>177</sup>Lu]Lu-DOTATATE in meningiomas expressing SSTR2, improving progression-free survival (PFS) in refractory cases.</div><div>Current evidence suggests that PRRT is a viable option for refractory meningiomas with high SSTR expression. However, further clinical trials are needed to establish standardized protocols, optimize patient selection criteria, and explore combination therapy strategies to improve outcomes. This review highlights the mechanisms, clinical applications, and future perspectives of [<sup>177</sup>Lu]Lu-DOTATATE in meningiomas, providing insights into its expanding role in this pathology.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"45 1","pages":"Article 500218"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146006774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Linfoma T celular angioinmunoblástico con afectación tiroidea en la 18F-FDG PET/TC 18F-FDG PET/TC甲状腺病变的血管免疫成形术T细胞淋巴瘤

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2026-01-01 DOI: 10.1016/j.remn.2025.500177

Y. Li, X. Zhang, Z.-X. He

引用次数: 0

Alteraciones metabólicas en PET cerebral con [18F]FDG en un caso de amnesia global transitoria postcoital [18F]FDG脑PET代谢紊乱在性交后暂时性全面性失忆症病例中的作用

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2026-01-01 DOI: 10.1016/j.remn.2025.500203

F. Sebastián Palacid, B. Pérez López, N. Álvarez Mena, C. Riola Parada, C. Gamazo Laherrán, R. Ruano Pérez

引用次数: 0

Evaluación comparativa de los resultados de la PET/TC con [18F]F-PSMA-1007 y la PET/TC con [68Ga]Ga-PSMA-11 en los pacientes con recidiva bioquímica de cáncer de próstata 前列腺癌生化复发患者PET/TC与[18F]F-PSMA-1007和PET/TC与[68Ga]Ga-PSMA-11的疗效比较评价

IF 1.6 4区医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Revista Espanola De Medicina Nuclear E Imagen Molecular

Pub Date : 2026-01-01 DOI: 10.1016/j.remn.2025.500178

G. Inal , C. Soydal , B. Demir , M. Araz , Y. Urun , S. Baltacı , E. Suer , N.O. Kucuk

Aim

In this study, we aimed to evaluate the diagnostic performance of ¹⁸F-PSMA-1007 PET/CT compared to ⁶⁸Ga-PSMA-11 PET/CT, which is more commonly used in routine practice, for detecting prostate cancer recurrence in prostate cancer patients with biochemical recurrence.

Materials and methods

Forty-one prostate cancer patients with biochemical recurrence were prospectively included in the study. Additionally, images from 46 patients in our institution's database, who had undergone ⁶⁸Ga-PSMA-11 PET/CT imaging for biochemical recurrence, were retrospectively re-evaluated to compare the detection rates with those of ¹⁸F-PSMA-1007 PET/CT. SUVmax, total tumor PSMA, PSMA total tumor volume were calculated for local recurrence, lymph node metastasis, and organ metastasis. The diagnostic performances of the two imaging methods were then compared.

Results

The mean age, Gleason scores, ISUP scores, serum PSA levels at diagnosis and at the time of imaging, and PSA doubling times were similar across the ¹⁸F-PSMA-1007 and ⁶⁸Ga-PSMA-11 groups. Pathological uptake was observed in the prostatic bed in 16 patients (39.0%), lymph nodes in 22 patients (46.3%), and bones in 11 patients (26.8%) with ¹⁸F-PSMA-1007 PET/CT. ¹⁸F-PSMA-1007 PET/CT showed statistically significant superiority over ⁶⁸Ga-PSMA-11 PET/CT in detecting lymph node metastases (41.6% vs. 25.4%; P = .028). There was no significant difference between the two imaging protocols in the detection rates of local recurrence (P = .067) and bone metastasis (P = .580).

Conclusion

Although the study included a small sample size, the results revealed that ¹⁸F-PSMA-1007 PET/CT had a higher detection rate than ⁶⁸Ga-PSMA-11 PET/CT in patients with biochemically recurrent prostate carcinoma, particularly for lymph node metastases.

在本研究中，我们旨在评价18F-PSMA-1007 PET/CT与68Ga-PSMA-11 PET/CT在前列腺癌生化复发患者中对前列腺癌复发的诊断价值。材料与方法前瞻性纳入41例生化复发的前列腺癌患者。此外，我们对我院数据库中46例接受68Ga-PSMA-11 PET/CT成像诊断生化复发的患者的图像进行回顾性重新评估，比较其检出率与18F-PSMA-1007 PET/CT的检出率。计算肿瘤局部复发、淋巴结转移、器官转移的SUVmax、肿瘤总PSMA、PSMA肿瘤总体积。然后比较两种成像方法的诊断性能。结果18F-PSMA-1007组和68Ga-PSMA-11组患者的平均年龄、Gleason评分、ISUP评分、诊断时和成像时血清PSA水平、PSA翻倍次数相似。18F-PSMA-1007 PET/CT显示，前列腺床16例（39.0%），淋巴结22例（46.3%），骨骼11例（26.8%）。18F-PSMA-1007 PET/CT在淋巴结转移检测方面优于68Ga-PSMA-11 PET/CT （41.6% vs. 25.4%, P = 0.028）。两种影像学检查方案在局部复发检出率（P = 0.067）和骨转移检出率（P = 0.580）方面差异无统计学意义。结论虽然本研究样本量较小，但结果显示18F-PSMA-1007 PET/CT对生化复发前列腺癌患者，尤其是淋巴结转移患者的检出率高于68Ga-PSMA-11 PET/CT。

{"title":"Evaluación comparativa de los resultados de la PET/TC con [18F]F-PSMA-1007 y la PET/TC con [68Ga]Ga-PSMA-11 en los pacientes con recidiva bioquímica de cáncer de próstata","authors":"G. Inal , C. Soydal , B. Demir , M. Araz , Y. Urun , S. Baltacı , E. Suer , N.O. Kucuk","doi":"10.1016/j.remn.2025.500178","DOIUrl":"10.1016/j.remn.2025.500178","url":null,"abstract":"<div><h3>Aim</h3><div>In this study, we aimed to evaluate the diagnostic performance of <sup>18</sup>F-PSMA-1007 PET/CT compared to <sup>68</sup>Ga-PSMA-11 PET/CT, which is more commonly used in routine practice, for detecting prostate cancer recurrence in prostate cancer patients with biochemical recurrence.</div></div><div><h3>Materials and methods</h3><div>Forty-one prostate cancer patients with biochemical recurrence were prospectively included in the study. Additionally, images from 46 patients in our institution's database, who had undergone <sup>68</sup>Ga-PSMA-11 PET/CT imaging for biochemical recurrence, were retrospectively re-evaluated to compare the detection rates with those of <sup>18</sup>F-PSMA-1007 PET/CT. SUVmax, total tumor PSMA, PSMA total tumor volume were calculated for local recurrence, lymph node metastasis, and organ metastasis. The diagnostic performances of the two imaging methods were then compared.</div></div><div><h3>Results</h3><div>The mean age, Gleason scores, ISUP scores, serum PSA levels at diagnosis and at the time of imaging, and PSA doubling times were similar across the <sup>18</sup>F-PSMA-1007 and <sup>68</sup>Ga-PSMA-11 groups. Pathological uptake was observed in the prostatic bed in 16 patients (39.0%), lymph nodes in 22 patients (46.3%), and bones in 11 patients (26.8%) with <sup>18</sup>F-PSMA-1007 PET/CT. <sup>18</sup>F-PSMA-1007 PET/CT showed statistically significant superiority over <sup>68</sup>Ga-PSMA-11 PET/CT in detecting lymph node metastases (41.6% vs. 25.4%; <em>P</em>  =.067) and bone metastasis (<em>P</em>  <!-->.580).</div></div><div><h3>Conclusion</h3><div>Although the study included a small sample size, the results revealed that <sup>18</sup>F-PSMA-1007 PET/CT had a higher detection rate than <sup>68</sup>Ga-PSMA-11 PET/CT in patients with biochemically recurrent prostate carcinoma, particularly for lymph node metastases.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"45 1","pages":"Article 500178"},"PeriodicalIF":1.6,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146006828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Revista Espanola De Medicina Nuclear E Imagen Molecular

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀